Clinical Trial: RPC1063 (Receptos, Inc.) - National Multiple Sclerosis Society

Skip to navigation Skip to content

Clinical Trial: RPC1063 (Receptos, Inc.)

Share

Details
Type of MS: RRMS
Treatment mode of action: To affect immune function
Number of Subjects: 1410
Medication: RPC1063
Location: CA|FL|NC|OH|WA
Contact Information
Jeff Hartung
(858) 652-5736

Funding:

Receptos, Inc.

Description

To determine safety and effectiveness of RPC1063, a selective sphingosine 1-phosphate receptor modulator, in people with relapsing MS.

Share